Call Now

Cynomolgus / Rhesus c-MET / HGFR Protein (His Tag)

MET

Catalog Number P90304-C08H
Organism Species Cynomolgus
Host Human Cells
Synonyms MET
Molecular Weight The recombinant cynomolgus/rhesus MET comprises 919 amino acids and has a calculated molecular mass of 103.1 KDa. The apparent molecular mass of it is approximately 128.2, 77.6 and 45.7 KDa in SDS-PAGE under reducing conditions.
predicted N Glu 25
SDS-PAGE
Purity (4.6+58.2+34.7) % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the cynomolgus/rhesus MET (NP_001162100.1) (Met1-Thr932) was expressed with a polyhistidine tag at the C-terminus. Cynomolgus and Rhesus MET sequences are identical.
Bio-activity Immobilized Cynomolgus MET-His at 10 μg/ml (100 μl/well) can bind biotinylated Cynomolgus HGF (cat:90286-CNAH), The EC50 of biotinylated Cynomolgus HGF (cat:90286-CNAH) is 0.11-0.27 μg/ml.
Research Area Cancer |Signal transduction |Protein Phosphorylation |Tyrosine Kinase |Receptor Tyrosine Kinases
Formulation Lyophilized from sterile PBS, pH 7.4.
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that has been shown to be overexpressed and/or mutated in a variety of malignancies. HGFR protein is produced as a single-chain precursor, and HGF is the only known ligand. Normal HGF/HGFR signaling is essential for embryonic development, tissue repair or wound healing, whereas aberrantly active HGFR has been strongly implicated in tumorigenesis, particularly in the development of invasive and metastatic phenotypes. HGFR protein is a multifaceted regulator of growth, motility, and invasion, and is normally expressed by cells of epithelial origin. Preclinical studies suggest that targeting aberrant HGFR signaling could be an attractive therapy in cancer.
Reference
  • McGill GG, et al. (2006) c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem. 281(15): 10365-73.
  • Garcia S, et al. (2007) c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. British journal of cancer. 96(2): 329-35.
  • Socoteanu MP, et al. (2008) c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 14(19): 2990-4.
  • Kong DS, et al. (2009) Prognostic significance of c-Met expression in glioblastomas. Cancer. 115(1): 140-8.